Watson Pharmaceuticals (WPI -0.25%) sues the FDA for "improperly" denying the company's shared...
Watson Pharmaceuticals (WPI -0.25%) sues the FDA for "improperly" denying the company's shared exclusivity for a generic version of Type 2 diabetes drug Actos despite the firm following the agency's directions. As a result of the FDA's decision, Watson's abbreviated new drug application (ANDA) could be delayed for up to six months.
From other sites
Video at CNBC.com (Aug 6, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs